DNA topoisomerases as targets for anticancer drugs

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• DNA topoisomerases are vital enzymes regulating DNA topology during cellular processes.
• Inhibitors of DNA topoisomerases have emerged as a significant class of anticancer therapeutics.
• Understanding these enzymes is key to developing effective cancer treatments.

Purpose of the Study:

• To review current topoisomerase-targeting drugs with demonstrated anticancer activity.
• To elucidate the mechanisms by which these drugs inhibit Type I and Type II DNA topoisomerases.
• To discuss the factors contributing to the development of drug resistance.

Main Methods:

• Literature review of pharmacological studies on DNA topoisomerase inhibitors.
• Analysis of drug mechanisms targeting the catalytic cycle of topoisomerases.
• Examination of research on resistance mechanisms to topoisomerase-targeting drugs.

Main Results:

• Several topoisomerase-targeting drugs exhibit significant anticancer potential.
• These drugs function by interfering with the DNA breakage and rejoining activities of topoisomerases.
• Drug resistance can arise through various cellular mechanisms, impacting treatment efficacy.

Conclusions:

• DNA topoisomerase inhibitors represent a promising avenue for cancer therapy.
• Further research into drug mechanisms and resistance is essential for optimizing treatment strategies.
• Targeting DNA topoisomerases remains a key focus in anticancer drug development.